Clearside Biomedical, Inc.

NasdaqGM:CLSD 株式レポート

時価総額:US$77.4m

Clearside Biomedical 過去の業績

過去 基準チェック /06

Clearside Biomedicalの収益は年間平均-7.6%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間1.2% 5.5%割合で 増加しています。

主要情報

-7.6%

収益成長率

8.9%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率5.5%
株主資本利益率n/a
ネット・マージン-413.8%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

収支内訳

Clearside Biomedical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:CLSD 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 248-321221
30 Jun 248-331122
31 Mar 248-351222
31 Dec 238-321221
30 Sep 232-371220
30 Jun 232-361219
31 Mar 231-351120
31 Dec 221-331220
30 Sep 2227-51218
30 Jun 2229-21219
31 Mar 223001218
31 Dec 213001219
30 Sep 214-251119
30 Jun 214-231118
31 Mar 214-231117
31 Dec 208-181115
30 Sep 2010-141212
30 Jun 207-18139
31 Mar 206-18169
31 Dec 192-311716
30 Sep 190-491732
30 Jun 190-671752
31 Mar 190-821666
31 Dec 180-831568
30 Sep 180-781365
30 Jun 180-721161
31 Mar 180-651055
31 Dec 170-591049
30 Sep 170-521042
30 Jun 170-39930
31 Mar 170-31822
31 Dec 161-26619
30 Sep 161-21516
30 Jun 161-19515
31 Mar 161-19713
31 Dec 150-18711
30 Sep 150-1569
30 Jun 150-1569
31 Mar 150-1248
31 Dec 140-1037
30 Sep 140-936
30 Jun 140-835
31 Mar 140-825

質の高い収益: CLSDは現在利益が出ていません。

利益率の向上: CLSDは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CLSDは利益が出ておらず、過去 5 年間で損失は年間7.6%の割合で増加しています。

成長の加速: CLSDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CLSDは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 54.6% ) と比較することは困難です。


株主資本利益率

高いROE: CLSDの負債は資産を上回っているため、自己資本利益率を計算することは困難です。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘